Sonavex raises $3M for ultrasound blood-clot detector

Baltimore-based Sonavex is developing a device that uses ultrasound to screen for blood clots post-surgery.

Johns Hopkins spinout Sonavex reeled in $3 million, including $2.2 million from the first close of its Series A round, which will drive the commercialization of the company’s ultrasound device that detects blood clots in patients after surgery.

While ultrasound is useful for monitoring blood flow, sonographers must be trained to interpret the images. Sonavex’s EchoSure technology is a doppler ultrasound system that automatically detects blood flow loss, making it possible for non-sonographers to monitor blood flow. It would be useful for the monitoring of patients who have undergone procedures that involve surgically connecting arteries and veins, the company said.

Catching postoperative clots early allows physicians to intervene quickly to prevent vessel blockage and surgical failure.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

RELATED: GE Healthcare, Endra partner to improve point-of-care ultrasound for fatty liver

“Our ultrasound technology offers a game-changing solution to a catastrophic problem for patients,” said Sonavex Chief Medical Officer Devin O’Brien Coon, M.D., in a statement. “For decades, surgeons have sought a reliable way to detect early thrombosis after surgery and we are eager to begin using EchoSure in the clinic.”

The funding comprises $2.2 million in equity and another $750,000 in a Small Business Innovation Research grant from the National Science Foundation, according to the statement. In addition to bankrolling the commercialization of the EchoSure technology, the funds will support the development of Sonavex’s pipeline of perioperative ultrasound solutions, the company said.

Grey Sky Venture Partners led the financing, while CRCM Venture Capital, TEDCO and the Abell Foundation also participated.


Suggested Articles

The Chan Zuckerberg Initiative is awarding $17 million for advances in digital microscopy to allow researchers to view the subtleties of disease.

Biotronik received FDA approvals for six high-voltage cardiac rhythm management devices for treating and resynchronizing tachycardia and arrhythmias.

IRhythm’s ECG patch was able to improve atrial fibrillation diagnoses and lower numbers of ER visits by shifting patients to outpatient settings.